CoChat

Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Dasatinib is a multitargeted kinase inhibitor that was recently approved for the treatment of chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. It is also in clinical trials for treating patients with solid tumors. The identification of molecular markers predictive of response to dasatinib could assist in clinical development by selecting patients most likely to derive clinical benefit. Using baseline gene expression profiling of a panel of 23 breast cancer cell lines, we identified genomic signatures highly correlated with in vitro sensitivity to dasatinib. The ability of these signatures to predict dasatinib sensitivity was further confirmed and validated in independent test cell lines. A six-gene model was used to correctly predict dasatinib sensitivity in 11 out of 12 (92%) additional breast and 19 out of 23 (83%) lung cancer cell lines. Quantitative real-time PCR and immunohistochemical assays further confirmed the differential expression pattern of selected markers. Finally, these gene signatures were observed in a subset of primary breast, lung, and ovarian tumors suggesting potential utility in patient selection. The subset of breast cancer patients expressing the dasatinib-sensitive signature includes a distinct clinical and molecular subgroup: the so-called “triple negative” (i.e., estrogen receptor–negative, progesterone receptor–negative, and HER2-negative) or “basal” breast cancer subtype. This patient population has a poor prognosis and currently has few effective treatment options. Our results implicate that dasatinib may represent a valuable treatment option in this difficult-to-treat population. To test this hypothesis, clinical studies are now under way to determine the activity of dasatinib in these patients. [Cancer Res 2007;67(5):2226–38]

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-3633

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 49 references

Research works printed but not linked: 1

  1. Finn RS, Dering J, Wilson CA, et al. Biologic effects and identification of predictive markers of response to Dasatinib (BMS-354825), novel, oral, multi-targeted kinase inhibitor in human breast cancer cell lines in vitro. Clin Cancer Res 2005; 11: 9022s.

Cited by

See all 346

Metadata

Authors
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E.
Affiliations
  • 1Clinical Discovery and Departments of
  • Bristol-Myers Squibb (United States) (US)
Venue
Cancer Research
Published
2007-03-01
Volume
67
Issue
5
Pages
2226-2238
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2044858733
Cited by
344
References
48
Citations by year
2026: 2 · 2025: 3 · 2024: 6 · 2023: 20 · 2022: 12 · 2021: 17 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 10 · 2016: 12 · 2015: 13 · 2014: 24 · 2013: 18 · 2012: 22
FWCI
14.79
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
dasatinib, molecular markers, drug response prediction, kinase inhibitors, breast cancer cell lines, lung cancer cell lines, ovarian cancer, gene expression signatures, triple-negative breast cancer, basal-like breast cancer, patient selection, multikinase inhibitor
MeSH terms
Dasatinib, Antineoplastic Agents, Breast Neoplasms, Humans, Models, Genetic, Prognosis, Pyrimidines, Thiazoles, Biomarkers, Tumor, Patient Selection, Drug Resistance, Neoplasm, Gene Expression Profiling, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-3633
The paper
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007). Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-3633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.